pulmonary hypertension and scleroderma life expectancy

The life expectancy of individuals with pulmonary arterial hypertension (PAH) and systemic sclerosis (SSc) is often reduced due to the combined effects of these two conditions. PAH is characterized by abnormally high pulmonary artery pressure, which increases the workload on the right ventricle of the heart and can ultimately lead to heart failure. SSc, on the other hand, is an autoimmune disease marked by fibrosis of the skin and internal organs. Both conditions can negatively impact survival rates.

In more detail, the five-year survival rate for PAH patients is approximately 50-75%, while for SSc patients it ranges from 80-90%. However, when both diseases are present simultaneously, the survival rate may decline further. This is because SSc can intensify the symptoms of PAH and complicate treatment.

For patients who have both PAH and SSc, it is crucial to seek medical attention promptly and receive specialized care. Additionally, patients should adhere to their physician's recommendations, undergo regular follow-up appointments, and be mindful of their diet and exercise routines. Regarding pharmacological therapy, patients must strictly follow their doctor's prescriptions, refraining from altering dosages or switching medications without guidance. By doing so, the chances of improving both survival rates and quality of life can be significantly enhanced.